Evidence map›Paper›PMID 37016726›Full record

ArticleJournal of biopharmaceutical statistics2024

Assessing the incidence and severity of drug adverse events: a Bayesian hierarchical cumulative logit model.

Jiawei Duan, Byron J Gajewski, Paramita Sen, Jo A Wick

Abstract read
In one paragraph

Article in Journal of biopharmaceutical statistics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jiawei DuanGlobal Drug Development, Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, New Jersey, USA.ORCID 0000-0001-8979-1651
Byron J GajewskiDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas, USA.
Paramita SenGlobal Drug Development, Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, New Jersey, USA.
Jo A WickDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas, USA.

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
NCI NIH HHS P30 CA168524
6 · The paper itself

Abstract

Detection of safety signals based on multiple comparisons of adverse events (AEs) between two treatments in a clinical trial involves evaluations requiring multiplicity adjustment. A Bayesian hierarchical mixture model is a good solution to this problem as it borrows information across AEs within the same System Organ Class (SOC) and modulates extremes due merely to chance. However, the hierarchical model compares only the incidence rates of AEs, regardless of severity. In this article, we propose a three-level Bayesian hierarchical non-proportional odds cumulative logit model. Our model allows for testing the equality of incidence rate and severity for AEs between the control arm and the treatment arm while addressing multiplicities. We conduct simulation study to investigate the operating characteristics of the proposed hierarchical model. The simulation study demonstrates that the proposed method could be implemented as an extension of the Bayesian hierarchical mixture model in detecting AEs with elevated incidence rate and/or elevated severity. To illustrate, we apply our proposed method using the safety data from a phase III, two-arm randomized trial.

Indexed as

Logistic ModelsBayes TheoremClinical Trials, Phase III as TopicComputer SimulationHumansIncidenceProbabilityRandomized Controlled Trials as TopicBayesian mixture modelDrug safetymultiplicitynon-proportional odds cumulative logit modelsafety signal detection

Identifiers

PMID37016726
PMCPMC10552594

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.